Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.

ABSTRACT:

Objectives

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of several locally advanced and metastatic tumors. They enhance the effector function of the immune system, consequently leading to different immune-related adverse events. The aim of the present study was to describe three cases of dermatomyositis (DM) triggered by ICI diagnosed at our institution and to perform a review of the literature.

Methods

We performed a retrospective clinical, laboratory, and pathological evaluation of three cases of DM triggered by ICI belonging to a cohort of 187 DM patients from the Clinic Hospital Muscle Research Group of Barcelona from January 2009 to July 2022. Moreover, we undertook a narrative review of the literature from January 1990 to June 2022.

Results</

SUBMITTER: Guerra NL 

PROVIDER: S-EPMC10529928 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature